SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability

Atorvastatin, prescribed for the treatment of hypercholesterolemia, demonstrated overwhelming benefits in reducing cardiovascular morbidity and mortality. However, many patients discontinue therapy due to adverse reactions, especially myopathy. The Dutch Pharmacogenetics Working Group (DPWG) recomme...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Pers Med
Main Authors: Zubiaur, Pablo, Benedicto, Maria Dolores, Villapalos-García, Gonzalo, Navares-Gómez, Marcos, Mejía-Abril, Gina, Román, Manuel, Martín-Vílchez, Samuel, Ochoa, Dolores, Abad-Santos, Francisco
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7999651/
https://ncbi.nlm.nih.gov/pubmed/33805706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11030204
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki